Cheap and widely available drug cuts down risk of Covid death: Dr Chandima Jeewandara
A cheap and widely available drug used to treat mental illness cuts both the risk of death from Covid-19 and the need for people with the disease to receive intensive medical care according to clinical trial results, stated Sri Jayewardenepura University’s Allergy, Immunology, and Cell Biology Unit Director Dr. Chandima Jeewandara.
He made this known via a twitter post yesterday (02).
When contacted by The Morning, Dr Jeewandara said that among study participants, the death rate from Covid-19 dropped by 90% and the need for medical care dropped by 65%.
“Fluvoxamine is taken for conditions including depression and obsessive–compulsive disorder. Among study participants who took the drug as directed and did so in the early stages of the disease, Covid-19-related deaths fell by roughly 90% and the need for intensive Covid-19-related medical care fell by roughly 65%,” said Jeewandara.
Jeewandara confirmed that the study included 1,497 people in Brazil who had Covid-19 and were at high risk of severe disease. Roughly half received fluvoxamine, and the rest received a placebo.